Enjoy complimentary customisation on priority with our Enterprise License!
The primary immunodeficiency therapeutics market size is forecast to increase by USD 1.70 billion at a CAGR of 4.5% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of immunodeficiency diseases worldwide. According to the World Health Organization, an estimated 350 million people are living with immunodeficiencies, making it a major public health concern. The market is also driven by the increasing research and development (R&D) activities in this field, as pharmaceutical companies invest heavily in the discovery and development of new and innovative therapies. However, the side effects of immunotherapy, such as cytokine release syndrome and immunogenicity, pose challenges to market growth. Despite these challenges, the market is expected to continue expanding, driven by the unmet medical needs of patients with primary immunodeficiencies and the ongoing advancements in immunotherapeutic technologies.
Primary immunodeficiency diseases encompass a range of genetic disorders characterized by antibody deficiency, cellular immunodeficiency, and innate immune disorders. These conditions result in recurring infections, tumors, and genetic abnormalities. Therapeutic interventions for primary immunodeficiencies include immunoglobulin replacement therapy, which involves administering proteins to replace missing or deficient antibodies. Stem cell and bone marrow transplantation offer potential cures for some types of immunodeficiencies. Antibiotic therapy is used to prevent and treat infections. Gene therapy and genetic therapy hold promise for correcting the underlying genetic causes of these disorders. Hospitals and clinics provide diagnostic tests, such as genetic testing and diagnostic technologies, to identify and diagnose primary immunodeficiencies.
Supportive care, including proper nutrition and vaccinations, also plays a crucial role in managing these conditions. Immunodeficiency diseases include rheumatoid disease, deficiency anemia, hypothyroidism, and various other conditions. Therapies continue to evolve, with a focus on developing more effective and personalized treatments for this diverse group of disorders.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The antibody deficiency segment is estimated to witness significant growth during the forecast period. Primary immunodeficiency diseases encompass a range of genetic disorders that impair the function of immune cells and proteins, leading to recurring infections, tumors, and other health complications. The global market in 2023 is dominated by antibody deficiency, which accounts for a significant market share. Antibody deficiency, also known as humoral immunodeficiency, primarily affects B cells and their production of immunoglobulins. Approximately half of all primary immunodeficiency diagnoses involve antibody deficiencies. Cellular immunodeficiencies, another segment of primary immunodeficiency diseases, affect the function of T and NK cells. Innate immune disorders, such as rheumatoid disease, deficiency anemia, hypothyroidism, lymphoma, neurologic disorders, arrhythmias, electrolyte disorders, and coagulopathies, also fall under the primary immunodeficiency category.
Various therapeutic approaches are employed to manage primary immunodeficiency diseases, including immunoglobulin replacement therapy, stem cell and bone marrow transplantation, antibiotic therapy, gene therapy, and immunomodulatory drugs. Diagnostic tests, such as genetic testing and diagnostic technologies, play a crucial role in identifying these disorders. Immunoglobulin therapy, which involves the administration of antibodies to replace the deficient ones, is a common treatment for antibody deficiencies. Antibiotics are used to prevent and treat infections in patients with primary immunodeficiencies. Hospitals and clinics are major end-users of primary immunodeficiency therapeutics due to the high prevalence of these disorders and the need for specialized care.
Some of the primary immunodeficiency diseases include X-linked SCID, Wiskott Aldrich Syndrome, and non-Hodgkin's lymphoma. These disorders can lead to weight loss, rhinitis, atopic dermatitis, and other complications. Gene therapy and genetic testing are emerging as promising therapeutic approaches for primary immunodeficiencies, offering the potential for long-term cure and improved quality of life for patients.
Get a glance at the market share of various segments Request Free Sample
The antibody deficiency segment was valued at USD 2.50 billion in 2018 and showed a gradual increase during the forecast period.
Europe is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
Immunodeficiency diseases encompass a range of conditions resulting from both antibody deficiency and cellular immunodeficiencies, including innate immune disorders. These diseases are characterized by recurring infections, tumors, and genetic abnormalities. Immunoglobulin replacement therapy, such as Immunoglobulin Therapy, is a common treatment for antibody deficiencies, while stem cell and bone marrow transplantation address cellular immunodeficiencies. Antibiotic therapy is used to prevent and treat infections in individuals with immunodeficiencies. Innate immune disorders, like rheumatoid disease, deficiency anemia, hypothyroidism, lymphoma, neurologic disorders, arrhythmias, electrolyte disorders, and coagulopathies, may benefit from gene therapy and genetic testing for diagnosis and treatment. Immunodeficiency diseases also manifest in weight loss, rhinitis, atopic dermatitis, X-linked SCID, Wiskott Aldrich Syndrome, non-Hodgkin's lymphoma, rheumatoid arthritis, and other conditions.
Supportive care and diagnostic technologies play crucial roles in managing these complex diseases. Hospitals and clinics provide essential services for diagnosing and treating immunodeficiencies, ensuring patients receive appropriate therapies to improve their quality of life.
Our primary immunodeficiency therapeutics market researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increasing prevalence of immunodeficiency diseases is notably driving the market growth. The global market is anticipated to experience significant growth during the forecast period due to the rising prevalence of immunodeficiency diseases. For instance, Adenosine deaminase deficiency, a rare disorder responsible for approximately 15% of severe combined immunodeficiency syndrome (SCID) cases, is estimated to occur in approximately 1 in 200,000 to 1,000,000 newborns worldwide. Moreover, according to the World Health Organization (WHO), around 1.5 million new HIV infections were reported globally in 2020, with 37.6 million people living with HIV, which causes acquired immunodeficiency disorder syndrome (AIDS). In the US, the prevalence of primary immunodeficiency disorders (PIDDs) is estimated at 1 in 2000 individuals.
Advancements in diagnostic tools such as flow cytometry and next-generation sequencing, along with the development of targeted therapies, gene therapies, biologics, and immunomodulatory drugs, are expected to provide significant opportunities for market growth. Healthcare regulatory scenarios and healthcare expenditure will also impact the market dynamics. The use of line curve analysis in evaluating the effectiveness of these therapies will further boost market growth.
Increasing R&D activities is the upcoming trend in the market. The market is projected to experience significant growth during the forecast period, driven by the increasing number of research and development (R&D) initiatives by vendors. These efforts are focused on enhancing the efficacy of existing treatments and discovering new ones for primary immunodeficiency diseases. For instance, an investigational study conducted in the US and the UK, supported by the National Institutes of Health (NIH) in May 2021, reported that 96% of children receiving new experimental lentiviral gene therapy for immunodeficiency diseases experienced restored immune function. R&D will remain crucial in improving the chances of new primary immunodeficiency treatments and therapies.
To gain a competitive edge, companies are increasingly focusing on the development of custom-made medicines, including targeted therapies, gene therapies, biologics, and immunomodulatory drugs. Advanced technologies such as flow cytometry and next-generation sequencing are also being leveraged to enhance diagnostic accuracy and personalize treatment plans. Healthcare regulatory scenarios and healthcare expenditure will continue to influence market dynamics, shaping the competitive landscape and the adoption of these innovative therapies.
Side effects of immunotherapy is the major challenge that affects the growth of the market. The regulatory landscape for primary immunodeficiency therapies is complex, with varying scenarios across different regions. Regulatory agencies such as the FDA and EMA have stringent requirements for the approval of new therapies, which can add to the cost and time of bringing new treatments to market. Despite these challenges, the market is expected to continue growing due to the unmet medical need for effective treatments for primary immunodeficiencies. Despite the benefits of immunotherapies, they come with side effects, which can impact patients' quality of life. Side effects can occur at any point during and after treatment and vary by treatment type and the patient's overall health.
Healthcare professionals need to be vigilant in monitoring patients for signs of side effects and provide appropriate interventions to manage them effectively. Understanding the indications and managing side effects is crucial to optimizing patient outcomes and ensuring the best possible care.
The primary immunodeficiency therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
ADMA Biologics Inc.: The company provides primary immunodeficiency therapeutics that facilitate the body's natural ability to generate essential proteins.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market caters to the treatment of various immune deficiencies, including antibody deficiency and cellular immunodeficiency. These disorders encompass a range of conditions, such as innate immune disorders, rheumatoid disease, deficiency anemia, hypothyroidism, lymphoma, neurologic disorders, arrhythmias, electrolyte disorders, coagulopathies, weight loss, rhinitis, atopic dermatitis, X-linked SCID, Wiskott-Aldrich syndrome, non-Hodgkin's lymphoma, and rheumatoid arthritis. Treatment modalities for primary immunodeficiencies include immunoglobulin replacement therapy, stem cell transplantation, bone marrow transplantation, antibiotic therapy, gene therapy, and genetic therapy. Immunoglobulin therapy involves the administration of immunoglobulins to replace missing or deficient antibodies. Antibiotic therapy is used to prevent and treat infections. Gene therapy and genetic testing are employed to correct genetic abnormalities at their source.
Supportive care and diagnostic technologies, such as diagnostic tests, play a crucial role in the management of primary immunodeficiencies. Hospitals and clinics are key end-users of these therapeutics due to the recurring nature of infections and the complex nature of some of these disorders. The market is expected to grow due to the increasing prevalence of primary immunodeficiencies and the development of new and innovative therapies.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
136 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
|
Market Growth 2024-2028 |
USD 1.70 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
4.23 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
Europe at 38% |
|
Key countries |
US, Germany, China, UK, and Canada |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, and Takeda Pharmaceutical Co. Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Disease Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
